Clinical Trial

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2016-02-01; most recent amendment 2025-02-23.
Status change: Active, Not Recruiting → Recruiting 2023-11-16
Status change: Recruiting → Active, Not Recruiting 2021-04-08
Trial Details
NCT Number NCT02674100
Lead Sponsor University of Louisville
Collaborators: The Americas Hepato-Pancreato-Biliary Association
Conditions Pancreatic Cancer
Enrollment 500 participants
Start Date 2016-01
Primary Completion 2030-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-25